About: T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates
Creator	Liljeström, P Arribillaga, L Bartosch, B Cosset, F-L Heeney, J Inchauspe, G Lasarte, J Paranhos-Baccala, G Rollier, C Sutter, G Verschoor, E Drexhage, Jar
source	PMC
abstract	Immune responses against multiple epitopes are required for the prevention of hepatitis C virus (HCV) infection, and the progression to phase I trials of candidates may be guided by comparative immunogenicity studies in non-human primates. Four vectors, DNA, SFV, human serotype 5 adenovirus (HuAd5) and Modified Vaccinia Ankara (MVA) poxvirus, all expressing hepatitis C virus Core, E1, E2 and NS3, were combined in three prime-boost regimen, and their ability to elicit immune responses against HCV antigens in rhesus macaques was explored and compared. All combinations induced specific T-cell immune responses, including high IFN-γ production. The group immunized with the SFV+MVA regimen elicited higher E2-specific responses as compared with the two other modalities, while animals receiving HuAd5 injections elicited lower IL-4 responses as compared with those receiving MVA. The IFN-γ responses to NS3 were remarkably similar between groups. Only the adenovirus induced envelope-specific antibody responses, but these failed to show neutralizing activity. Therefore, the two novel regimens failed to induce superior responses as compared with already existing HCV vaccine candidates. Differences were found in response to envelope proteins, but the relevance of these remain uncertain given the surprisingly poor correlation with immunogenicity data in chimpanzees, underlining the difficulty to predict efficacy from immunology studies. SUPPLEMENTARY INFORMATION: The online version of this article (doi:10.1038/gt.2016.55) contains supplementary material, which is available to authorized users.
has issue date	2016-07-14(xsd:dateTime)
bibo:doi	10.1038/gt.2016.55
bibo:pmid	27416077
has license	no-cc
sha1sum (hex)	7d67e7ef4b8a49008ae8d88816b68811da0b1881
schema:url	https://doi.org/10.1038/gt.2016.55
resource representing a document's title	T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates
has PubMed Central identifier	PMC7091906
has PubMed identifier	27416077
schema:publication	Gene Ther
resource representing a document's body	covid:7d67e7ef4b8a49008ae8d88816b68811da0b1881#body_text
is schema:about of	named entity 'superior' named entity 'groups' named entity 'combinations' named entity 'Core' named entity 'HCV' named entity 'immunogenicity' named entity 'combinations' covid:arg/7d67e7ef4b8a49008ae8d88816b68811da0b1881 named entity 'rhesus macaques' named entity 'T-cell' named entity 'comparative' named entity 'compared' named entity 'receiving' named entity 'responses' named entity 'NS3' named entity 'induce' named entity 'studies' named entity 'receiving' named entity 'production' named entity 'responses' named entity 'neutralizing' named entity 'modalities' named entity 'Four' named entity 'immunogenicity' named entity 'antigens' named entity 'serotype' named entity 'MVA' named entity 'HCV' named entity 'NS3' named entity 'prime-boost' named entity 'candidates' named entity 'gene sequences' named entity 'adenovirus' named entity 'HCV' named entity 'HCV' named entity 'HCV' named entity 'vector' named entity 'poxvirus' named entity 'lymphoproliferative' named entity 'vector' named entity 'adenovirus' named entity 'cytokine' named entity 'gene' named entity 'adenovirus vaccine' named entity 'immune responses' named entity 'saline' named entity 'HCV' named entity 'IL-4' named entity 'prime-boost' named entity 'DNA, recombinant' named entity 'NS3' named entity 'outbred' named entity 'IgG' named entity 'lymphoproliferation' named entity 'expression vector' named entity 'ANOVA' named entity 'PBMCs' named entity 'HCV' named entity 'IL-4' named entity 'vaccine' named entity 'transfection' named entity 'HCV' named entity 'vaccine' named entity 'immunogenicity' named entity 'non-human primates' named entity 'HCV' named entity 'chimpanzees' named entity 'cytokine' named entity 'lymphoproliferation' named entity 'gene'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software